Prostate Cancer Research
The Urologic Oncology Program is the recipient of a $11 million Specialized Program of Research Excellence grant in prostate cancer, a George M. O'Brien Urology Research Center grant, a PO1 in prostate cancer metastasis to bone, and two T32 Urology Training Grants.
A SPORE is a type of research grant awarded by the National Cancer Institute through their Translational Research Program. Each SPORE concentrates on a specific cancer type -- in this case, prostate cancer -- focusing research on prevention, early detection, diagnosis and treatment of that cancer.
Active laboratory programs include work in the areas of prostate cancer genetics, gene discovery, metastasis, biomarker discovery, therapeutic development, and prostate and bladder cell biology. Recently, research has expanded broadly into specific evaluation of quality-of-life outcomes analyses for localized and metastatic bladder and prostate cancers. Clinical trials involving gene therapy, chemotherapy, immunotherapy and targeted agents are available for prostate, bladder and renal-cell cancers.
In addition, Urologic Oncology Program investigators participate in the Prostate Cancer Foundation's Clinical Research Consortium.
The consortium ensures that leading cancer centers maintain a robust infrastructure for conducting prostate cancer clinical trials. The U-M Comprehensive Cancer Center is one of eight leading prostate cancer programs that form the consortium. Together, these institutions collaborate to rapidly and efficiently develop promising prostate cancer therapies. To date, Prostate Cancer Foundation has provided more than $17 million to this effort. More information on this and other initiatives can be found on their www.prostatecancerfoundation.org.